Axcan & Eurand Announce Name Change
Axcan Intermediate Holdings Inc. recently announced it is changing its name to Aptalis Pharma. The rebranding follows the recently completed combination of two specialty pharma companies focused on gastrointestinal diseases: Axcan and Eurand. Aptalis Pharma also has a new corporate logo and website: www.APTALISPharma.com.
“Our new name, Aptalis, is intended to capture the essence of two great companies that have transformed into one combined organization. Aptalis brings together the strengths and capabilities of our employees, our robust portfolio and growing pipeline, our innovative platform technologies, and our exceptional manufacturing capabilities to exceed the expectations of customers and patients,” said Frank Verwiel, MD, President and Chief Executive Officer.
Aptalis currently markets several products around the world, including ZENPEP, CANASA, CARAFATE, PYLERA, LACTEOL, DELURSAN, and SALOFALK and has several compounds in various stages of development targeting unmet medical needs. The pipeline includes another recent acquisition, AEROQUIN from Mpex Pharmaceuticals, currently in Phase III clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.
Above all, Aptalis will continue to put patients and their caregivers at the center of everything it does, striving to improve their quality of care thanks to a broader range of products in cystic fibrosis and gastrointestinal disorders; robust pipeline, technology platform, and manufacturing capabilities; and skilled team of professionals with deep understanding of customers’ needs.
Moving forward customers will receive the same great level of service and dedication from Aptalis that they have come to expect from Axcan and Eurand.
“This is an exciting time for Aptalis on our journey to becoming the reference specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders,” added Dr. Verwiel.
Aptalis Pharma Inc., is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis has manufacturing and commercial operations in the
Total Page Views: 1590
